Sodium oxybate

Sodium oxybate (Xyrem) is a central nervous system (CNS) depressant used to treat cataplexy or excessive daytime sleepiness associated with narcolepsy. It is a sodium salt of [gamma-Hydroxybutyric acid], an endogenous cerebral inhibitory neurotransmitter and a metabolite of the inhibitory neurotransmitter GABA. Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse. Sodium oxybate has been misused to stimulate body growth and to induce euphoria, disinhibition, and sexual arousal as a “party drug” or “club drug.” For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries. An extended-release oral suspension formulation of sodium oxybate for narcolepsy, marketed under the brand name LUMRYZ, gained tentative FDA approval in July 2022 and was fully approved in May 2023. In some countries, sodium oxybate has been investigated and used in alcohol withdrawal syndrome (AWS) to aid abstinence maintenance in alcohol use disorders. Its therapeutic use is listed as alcohol dependence agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Sodium 4-hydroxybutyrate, Oxybate sodium and Sodium Oxybutyrate. It is listed as a controlled drug substance (Schedule III). Its PubChem CID is 23663870.

CAS No 502-85-2
Molecular Formula C4H7NaO3
Molecular Weight 126.09 g/mol
Synonyms sodium;4-hydroxybutanoate

Frequently Asked Questions